Call Now 888-679-5520

Could This New Discovery Lower Your Blood Sugar
And Support Healthy Nerve Function?

Dr. Matthew Solomon,
M.D. and Neurologist

Dr. Solomon is a medical doctor and neurologist. He completed his training at King’s College, University of London and at The Stanford University School of Medicine. He believes in a foundation of scientific research and natural approaches to wellness and health. His focus is to educate his patients and provide proven solutions for self-care that work.

*Individual results may vary depending on age, weight, and physical exercise.


  1. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Department of Epidemiology & Biostatistics, Erasmus University Medical School, Rotterdam, The Netherlands. Patients treated with insulin were at highest risk of dementia Neurology. 1999 Dec 10;53(9):1937-42.

  2. Steven E. Nissen, M.D., and Kathy Wolski, M.P.H. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes Our data suggest a cardiovascular risk associated with the use of rosiglitazone. N Engl J Med 2007; 56:2457-2471June 14, 2007DOI: 10.1056/NEJMoa072761

  3. Dara Hope Cohen and Derek LeRoith, Division of Endocrinology, Diabetes and Bone Diseases, The Samuel Bronfman Department of Medicine, Mount Sinai School of Medicine. Medications used to treat T2D may affect the risk of cancer and cancer-related mortality.

  4. Nolte Kennedy, M., Bedrich, M., White Gray, L., Kroon, L., & Demetsky, M. (2015). The liver and blood sugar. The liver acts as the body’s glucose (or fuel) reservoir, and helps to keep your circulating blood sugar levels and other body fuels steady and constant. Diabetes Education Online.

  5. Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011). Diabetic neuropathy: cellular mechanisms as therapeutic targets. New insights into the mechanisms leading to the development of diabetic neuropathy continue to point to systemic and cellular imbalances in metabolites of glucose and lipids. Nat Rev Neurol, 7(10), 573-83. doi: 10.1038/nrneurol.2011.137

  6. Sugimoto, K., Yasujima, M., & Yagihashi, S. (2008). Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des, 14(10), 953-61.

  7. J R Coll Physicians Edinb. 2017 Jun;47(2):168-171. doi: 10.4997/JRCPE.2017.216.Taylor R Magnetic Resonance Centre Campus For Ageing & Vitality Newcastle University. Now that type 2 diabetes can be understood as a simple reversible condition, its component parts can be examined during the period of return to normal glucose tolerance.

  8. Sarah Steven, Keiren G Hollingsworth, Ahmad Al-Mrabeh, Leah Avery, Benjamin Aribisala, Muriel Caslake, Roy Taylor. Pathophysiologic changes in responders and non-responders. Diabetes Care, March 2016 DOI: 10.2337/dc15-9422

  9. E. L. Lim,K. G. Hollingsworth,B. S. Aribisala,M. J. Chen,J. C. Mathers, and R. Taylor. [The study] carries major implications for information to be given to newly diagnosed patients, who should know that they have a potentially reversible condition and not one that is inevitably progressive. Diabetologia. 2011 Oct; 54(10): 2506–2514.